Diagnostic Reagents For Infectious Diseases Market Size, Share & Trends Analysis Report By Product (Molecular Reagents, Immunoassay Reagents), By Disease Area (Respiratory Infections, Enteric Infections), By Technology, By End Use, By Region, and Segment

Diagnostic Reagents For Infectious Diseases Market Summary

The global diagnostic reagents for infectious diseases market size was estimated at USD 3,475.31 millionin 2024 and is projected to reach USD 8,079.07 million by 2033, growing at a CAGR of 9.30% from 2025 to 2033. The market is primarily driven by the increasing prevalence of respiratory diseases and sexually transmitted infections (STIs).

Respiratory diseases, including influenza, COVID-19, pneumonia, and tuberculosis, have the highest prevalence worldwide. The UNICEF 2023 report stated that, every year, there are over 1,400 cases of pneumonia per 100,000 children worldwide, or one case per 71 children, with the highest incidences occurring in South Asia (2,500 cases per 100,000 children) and West and Central Africa (1,620 cases per 100,000) in 2023.

Moreover, the WHO estimated 10.8 million people worldwide became ill with tuberculosis, including 6.0 million men, 3.6 million women, and 1.3 million. Therefore, the rising prevalence rate is driving strong demand for advanced diagnostic technologies such as molecular diagnostics and point-of-care testing, fueling market growth. In addition, the rapid expansion of telemedicine services and the growing adoption of home-based testing solutions are further contributing to the market’s expansion.

Furthermore, rising global awareness and government-supported screening programs are encouraging early detection and prevention initiatives. The Journal of Global Health reported in May 2025 that the distribution and health impact of infectious disease outbreaks from 1996 to 2023 were globally assessed. The World Health Organization has identified approximately 30 priority pathogens, including monkeypox virus, dengue virus, and influenza A viruses, that could cause global public health emergencies. This updated list emphasizes the significance of focusing efforts on these high-risk infections due to their high transmissibility, virulence, and the scarcity of vaccines and treatment options. As global concerns such as climate change, deforestation, and growing urbanization increase the risk of these illnesses spreading, boosting the demand for infectious disease reagents.

Furthermore, the expansion of advanced molecular technologies in developing regions is playing a crucial role in driving market growth. Growing investments in healthcare infrastructure and increasing access to innovative diagnostic tools are enabling faster, cost-effective, and more accurate detection of infectious diseases. For instance, in January 2024, QIAGEN (Netherlands) launched testing panels for its QIAstat-Dx instruments, along with reagents, in India for rapid and accurate diagnosis of infectious diseases. Such initiatives are accelerating the adoption of molecular diagnostics in developing regions and significantly contributing to market growth.

Moreover, the increasing funding by governments to target pathogen genomic surveillance is boosting the demand for infectious disease reagents associated with molecular diagnostics. In February 2024, the WHO announced that donors had contributed USD 4 million to establish a catalytic grant fund for organizations working in pathogen genomic surveillance. The fund will support pilot projects worldwide, particularly in low- and middle-income countries. As laboratories implement these pilot projects, there is an increased need for molecular diagnostics reagents, including PCR kits, sequencing reagents, and other consumables. This expansion of testing capabilities ensures more frequent and routine use of reagents, creating sustained demand while enhancing global capacity to detect, prevent, and respond effectively to infectious disease outbreaks.

Global Diagnostic Reagents For Infectious Diseases Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global diagnostic reagents for infectious diseases market report based on product, disease area, technology, end-use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Molecular Reagents
• Immunoassay Reagents
• Rapid Test Reagents
• Serology Reagents
• Controls and Calibrators
• Other Reagents
• Disease Area Outlook (Revenue, USD Million, 2021 - 2033)
• Respiratory Infections
• Vector-Borne & Tropical Diseases
• Enteric Infections
• Sexually Transmitted Infections (STIs)
• Other Emerging / High-Burden Infectious Diseases
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Molecular Diagnostics
• Immunoassays
• Point-of-Care Reagents
• Multiplex Platforms
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Laboratories
• Point-of-Care / Decentralized Testing Sites
• Public Health Agencies & National Reference Labs
• Academic & Research Institutes
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Please note The report will be delivered in 2-3 business days upon order notification. Show more